REPLAY MaaT Pharma Investor Presentation.

Following the publication of its half-year results, MaaT Pharma decided to offer investors this opportunity to discuss the company’s strategy and outlook, as well as stock market-related topics. A live webcast was broadcast on October 2 at 7pm.

Hervé Affagard, CEO of MaaT Pharma, talks about the latest news, the construction of his plant and the company’s outlook.

And in view of the fall in the share price, Hervé Affagard tells investors in this presentation about the following elements linked to the share price

The company has “acquired the certainty that the fall in this share price was linked to an investor who participated in the IPO and who is in this unique situation, which concerns a single investor, who was in a position to have to sell.” Hervé Affagard also stated in this presentation: “And because of the confidence we have in the project and the fact that we also think the company is completely undervalued, quite simply, part of the management and the Board of Directors wanted to send out a strong signal and reaffirm confidence in MaaT Pharma’s fundamentals by buying back the shares from this shareholder who was a seller.”

At the time of the half-year results, MaaT Pharma stated: “The ARES study on MaaT013 has reached the threshold of patients required to plan the DSMB (Independent Monitoring and Review Board) review scheduled for early in the fourth quarter of 2023. The European Medicines Agency (EMA) has granted MaaT033 orphan drug status aimed at improving overall survival in patients receiving allogeneic hematopoietic stem cell transplantation (allo-GCSH). The first patient was treated in the Phase 1b IASO pilot study in amyotrophic lateral sclerosis (ALS) with MaaT033. Construction of the production plant completed in 12 months, in partnership with Skyepharma, and relocation of MaaT Pharma’s production and development teams to the new 1,600m² plant. At June 30, 2023, the cash and cash equivalents position stood at 35.1 million euros, with an expected horizon in the second quarter of 2024”.